Fewer than a tenth of people eligible to benefit from weight-loss injections including Wegovy have access to them, states the WHO as it issues its initial guidance on the medications.
Given over a billion people worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.
Based on forecasts, over two billion will be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that excess weight is a long-term condition that can be addressed with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to widespread availability to the jabs that can aid individuals in losing considerable weight, explains the body.
Skinny Jab Scarcity
Despite the present best projected case, the production of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, per the health organization.
The guideline encourages governments and firms to widen availability, through measures such as voluntary licensing.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Function
The injections imitate a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals reduce food intake.
People usually start to lose weight after several weeks of beginning the once-weekly jabs.
Studies points to people may see weight return within a year of stopping the drug, because their typical appetite return.
To be above a healthy weight elevates your risk for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
